Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. / Mohammed, Z. M. A.; McMillan, D. C.; Elsberger, B.; Going, J. J.; Orange, C.; Mallon, E.; Doughty, J. C.; Edwards, J.
In: British Journal of Cancer, Vol. 106, No. 2, 17.01.2012, p. 383-388.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer
A1 - Mohammed,Z. M. A.
A1 - McMillan,D. C.
A1 - Elsberger,B.
A1 - Going,J. J.
A1 - Orange,C.
A1 - Mallon,E.
A1 - Doughty,J. C.
A1 - Edwards,J.
AU - Mohammed,Z. M. A.
AU - McMillan,D. C.
AU - Elsberger,B.
AU - Going,J. J.
AU - Orange,C.
AU - Mallon,E.
AU - Doughty,J. C.
AU - Edwards,J.
PY - 2012/1/17
Y1 - 2012/1/17
N2 - <p>BACKGROUND: Immunohistochemistry of Ki-67 protein is widely used to assess tumour proliferation, and is an established prognostic factor in breast cancer. There is interest in automating the assessment of Ki-67 labelling index (LI) with possible benefits in handling increased workload, with improved accuracy and precision.</p><p>PATIENTS AND METHODS: Visual and automated assessment of Ki-67 LI and survival were examined in patients with primary operable invasive ductal breast cancer. Tissue microarrays (n=379 patients) immunostained for Ki-67 were scored visually and automatically with the Slidepath Tissue IA system.</p><p>RESULTS: Visual and automated Ki-67 LI were in excellent agreement (ICCC=0.96, P<0.001). On univariate analysis, visual (P<0.001) and automated Ki67 LI (P<0.05) were associated with cancer-specific survival in patients with invasive ductal breast cancer overall and in patients who received endocrine therapy (Tamoxifen) (P<0.01 for visual and P<0.05 for automated scoring).</p><p>CONCLUSION: Automated assessment of Ki-67 LI would appear to be comparable to visual Ki-67 LI. However, automated Ki-67 LI assessment was inferior in predicting cancer survival in patients with breast cancer, including patients who received Tamoxifen. British Journal of Cancer (2012) 106, 383-388. doi:10.1038/bjc.2011.569 www.bjcancer.com Published online 3 January 2012 (C) 2012 Cancer Research UK</p>
AB - <p>BACKGROUND: Immunohistochemistry of Ki-67 protein is widely used to assess tumour proliferation, and is an established prognostic factor in breast cancer. There is interest in automating the assessment of Ki-67 labelling index (LI) with possible benefits in handling increased workload, with improved accuracy and precision.</p><p>PATIENTS AND METHODS: Visual and automated assessment of Ki-67 LI and survival were examined in patients with primary operable invasive ductal breast cancer. Tissue microarrays (n=379 patients) immunostained for Ki-67 were scored visually and automatically with the Slidepath Tissue IA system.</p><p>RESULTS: Visual and automated Ki-67 LI were in excellent agreement (ICCC=0.96, P<0.001). On univariate analysis, visual (P<0.001) and automated Ki67 LI (P<0.05) were associated with cancer-specific survival in patients with invasive ductal breast cancer overall and in patients who received endocrine therapy (Tamoxifen) (P<0.01 for visual and P<0.05 for automated scoring).</p><p>CONCLUSION: Automated assessment of Ki-67 LI would appear to be comparable to visual Ki-67 LI. However, automated Ki-67 LI assessment was inferior in predicting cancer survival in patients with breast cancer, including patients who received Tamoxifen. British Journal of Cancer (2012) 106, 383-388. doi:10.1038/bjc.2011.569 www.bjcancer.com Published online 3 January 2012 (C) 2012 Cancer Research UK</p>
U2 - 10.1038/bjc.2011.569
DO - 10.1038/bjc.2011.569
M1 - Article
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 2
VL - 106
SP - 383
EP - 388
ER -